News

January 13, 2017

Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

December 29, 2016

Join Us for an Upcoming Webcast about SPINRAZA TM (nusinersen)

Please join Cure SMA, MDA and representatives from Biogen to learn more about SPINRAZA™ (nusinersen). As you know, SPINRAZA recently received FDA approval in the U.S. for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. In order to receive an update on SPINRAZA, please join this webcast, which is intended...

READ MORE   |  

Topics: Community & Awareness, Clinical Trials, Advocacy, Front Page News

December 23, 2016

Biogen Provides Community Statement and Q&A on the Approval of Spinraza for SMA

Biogen provided the following statement on the approval of Spinraza for SMA:

Dear Members of the SMA Community,

Today, the SMA community achieved a goal that would not have been possible without the support and dedication of the families, physicians and researchers who have passionately pursued a treatment for Spinal Muscular...

READ MORE   |  

Topics: Community & Awareness, Clinical Trials, Front Page News

Items 1 - 3 of 87  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software